Immunovant (IMVT)
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402,...
- Open
- 40.150
- High
- 40.955
- Low
- 38.610
- Prev. Close
- 39.900
- Volume
- 1.33M
- Turnover
- 52.42M
- Avg Price
- 39.382
- Bid/Ask Ratio
- 2.00%
- Amplitude
- 5.88%
- 52wk High
- 45.420
- Volume Ratio
- 0.86
- Turnover Ratio
- 1.50%
Immunovant Analyst Rating
View moreForecast & Rating
Aug 24, 2026Price forecast
$48.8823.77%
Forecast & RatingBuy
16analysts
- Strong buy62.50%
- Buy12.50%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 15 hours ago
Bank of New York Mellon Corp Acquires New Stake in Immunovant, Inc. $IMVT
- Global Report · 1 day ago, 10:13 AM
The Hidden Corners of the Market: Psychedelics, Data Centers, and the Micro-Catalyst Economy
- PUBT · Aug 28 at 08:29 PM
Immunovant director Atul Pande disposes of 1,500 common shares worth $64,905
- Market Beat · Aug 27 at 07:22 AM
Algert Global LLC Raises Position in Immunovant, Inc. $IMVT
- Tip Ranks · Aug 24 at 12:45 PM
UBS Remains a Hold on Immunovant (IMVT)
- PR Newswire · Aug 19 at 11:52 PM
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
